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A B S T R A C T
An essential aspect of stem cell in vitro culture and in vivo therapy is achieving sustained levels of growth factors
to support stem cell survival and expansion, while maintaining their multipotency and diﬀerentiation potential.
This study investigated the ability of dextrin (~74,000 g/mol; 27.8 mol% succinoylation) conjugated to epi-
dermal growth factor (EGF) and basic ﬁbroblast growth factor (bFGF; or FGF-2) (3.9 and 6.7% w/w protein
loading, respectively) to support the expansion and diﬀerentiation of stem cells in vitro via sustained, controllable
growth factor release. Supplementation of mouse neural stem cells (mNSCs) with dextrin-growth factor con-
jugates led to greater and prolonged proliferation compared to unbound EGF/bFGF controls, with no detectable
apoptosis after 7 days of treatment. Immunocytochemical detection of neural precursor (nestin) and diﬀer-
entiation (Olig2, MAP2, GFAP) markers veriﬁed that controlled release of dextrin-conjugated growth factors
preserves stem cell properties of mNSCs for up to 7 days. These results show the potential of dextrin-growth
factor conjugates for localized delivery of bioactive therapeutic agents to support stem cell expansion and dif-
ferentiation, and as an adjunct to direct neuronal repair.
1. Introduction
The transplantation of a variety of stem cells (embryonic, neural
stem cells (NSC) and non-neural (e.g. hematopoietic) stem cells) has
been widely investigated as a means of promoting repair and re-
generation following injury, due to their ability to self-renew and dif-
ferentiate into a wide range of cell types. Stem cell therapy shows
particular promise as a therapeutic tool to repair and regenerate the
nervous system in Parkinson's disease (Kim et al., 2002), neurodegen-
erative diseases such as Alzheimer's disease (Ager et al., 2015) and
following spinal cord injury (SCI) (Liu et al., 2013). However, their
clinical application is limited by the need to expand stem cell numbers
in vitro, while maintaining their multipotency and diﬀerentiation po-
tential. The importance of growth factors in maintaining stem cells in
an undiﬀerentiated state prior to implantation has necessitated the
addition of exogenous growth factors, such as basic ﬁbroblast growth
factor (bFGF; also known as FGF-2) and epidermal growth factor (EGF),
to in vitro culture media to promote cell proliferation, survival and
migration and reduce de-diﬀerentiation (Ciccolini et al., 2005; Dayer
et al., 2007; Sun et al., 2009; Tamama et al., 2010; Meng et al., 2008).
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However, since exogenous growth factors are rapidly degraded in cul-
ture medium (Lotz et al., 2013), standard methods require daily re-
placement of the medium, making stem cell culture expensive and
labor-intensive. Achievement of sustained levels of growth factors has
been shown to increase stem cell markers, decrease diﬀerentiation
markers and increase numbers of stem cells (Lotz et al., 2013). In vivo,
utilization of stem cell therapies is once again limited by the funda-
mental role of growth factors in neuronal survival, neurite outgrowth,
synaptic plasticity and neurotransmission (Gazdic et al., 2018). Despite
25 years of research and theoretical potential, recombinant growth
factors have had limited success in clinical practice; principally due to
their rapid clearance from the target site by diﬀusion and lymphatic
drainage, and premature inactivation by proteolytic enzymes and re-
active oxygen species in vivo. As a result, whilst clinical trials have
demonstrated the technique to be safe, attempts to induce healing using
stem cell implantation have shown only limited success clinically, with
typical survival rates of transplanted stem cells between 0.5 and 38%
(Walsh and Midha, 2009; Piltti et al., 2015).
Polymer therapeutics are increasingly being developed as in-
novative therapies for tissue repair and regeneration (Duncan and
Vicent, 2013). We have previously developed and characterized dex-
trin-growth factor conjugates using EGF as a model growth factor to
promote tissue repair (Hardwicke et al., 2008; Hardwicke et al., 2010a;
Hardwicke et al., 2010b; Hardwicke et al., 2011). Such conjugates ex-
hibit sustained and controlled degradation of the dextrin component in
the presence of physiological concentrations of α-amylase, an enzyme
that is widely distributed in extracellular ﬂuids and serum (30–110 IU/
L), leading to sustained release of free EGF, protein unmasking and
restoration of bioactivity to the level seen for unmodiﬁed EGF
(Hardwicke et al., 2008). In this wound healing model, we demon-
strated not only increased dermal cell proliferation and migration with
the dextrin-EGF, but also that the duration of eﬀect was longer than
that observed with free EGF (Hardwicke et al., 2008; Hardwicke et al.,
2010a). In an ex vivo organotypic model of re-epithelialisation, dextrin-
conjugated EGF was as eﬀective as free EGF at 10× lower doses
(Hardwicke et al., 2010b), and in an in vivo model of impaired wound
healing in diabetic (db/db) mice, topical application of dextrin-EGF
signiﬁcantly enhanced dermal wound healing (Hardwicke et al., 2011).
The potential for using such polymer therapeutics to support stem cell
therapy is clear, to both improve the eﬃciency and cost-eﬀectiveness of
in vitro stem cell expansion, and increase the survival, integration and
diﬀerentiation of transplanted stem cells in vivo. Encapsulation of
growth factors, such as FGF-2 (sold commercially as a growth factor
supplement (StemBeads®)) and vascular endothelial growth factor
(VEGF), into microparticles, has been tested as a means of achieving
sustained release for improved in vitro stem cell culture (Lotz et al.,
2013) and in vivo survival (Aday et al., 2017). The lack of a mechanism
to control the release/delivery of the growth factors in these systems
may, however, limit their use clinically.
The aim of this study was, therefore, to investigate the ability of two
model dextrin-growth factor conjugates (dextrin-EGF and dextrin-
bFGF) to support in vitro stem cell proliferation and diﬀerentiation by
sustained, controllable growth factor release and demonstrate their
potential as a supplement for stem cell therapy for pathologies such as
SCI. Dextrin-EGF and -bFGF conjugates have been synthesized and
characterized using fast protein liquid chromatography (FPLC), gel
permeation chromatography (GPC) and a bicinchoninic acid (BCA)
assay. Their ability to promote proliferation, prevent apoptosis and
regulate the diﬀerentiation of mouse neural stem cells (mNSCs) was
investigated in these studies.
2. Materials and methods
2.1. Materials and cells
Type 1 dextrin from corn (Mw ~ 51,000 g/mol) was from ML
laboratories (Keele, UK). Recombinant human EGF and recombinant
human bFGF were from Prospec-Tany Technogene Ltd. (Rehovot,
Israel). Anhydrous N,N-dimethyl formamide (DMF), 1-ethyl-3-(3-di-
methylaminopropyl carbodiimide hydrochloride) (EDC), copper (II)
sulfate pentahydrate 4% w/v solution, 3-(4,5-dimethylthiazol-2-yl)-2,5-
diphenyltetrazolium bromide (MTT), amylase from human saliva, and
bicinchoninic acid (BCA) solution were all from Sigma-Aldrich (Poole,
UK). Sodium acid phosphate, sodium phosphate, sodium chloride, N-
hydroxysulfosuccinimide (sulfo-NHS) and 4-dimethylaminopyridine
(DMAP) were from Fisher Scientiﬁc (Loughborough, UK). Pullulan gel
ﬁltration standards (Mw=11,800–788,000 g/mol) were from Polymer
Laboratories (U.K.). Unless otherwise stated, all chemicals were of
analytical grade. All solvents were of general reagent grade (unless
stated) and were from Fisher Scientiﬁc (Loughborough, UK).
Human epidermoid carcinoma (Hep2; ATCC no.: CCL-23) cells and
Eagle's minimum essential media (EMEM) with L-glutamine and Earle's
balanced salt solution adjusted to contain 1.5 g/L sodium bicarbonate,
non-essential amino acids and sodium pyruvate were purchased from
LGC Promochem (Teddington, UK). Primary neural stem cells (NSCs)
were derived from the embryonic mouse cortex on day E14 and cul-
tured using the neurosphere method described previously (Meng et al.,
2007). Cells were screened and found to be free of mycoplasma con-
tamination before use. DMEM/F12 media with L-glutamine, N2 sup-
plement, fetal calf serum (FCS), 0.05% w/w trypsin-0.53 mM EDTA,
antibiotic-antimycotic solution (containing penicillin G (10,000 units/
mL), streptomycin (10,000 μg/mL) and amphotericin B (25 μg/mL))
and StemPro®Accutase® were obtained from Invitrogen Life Technolo-
gies (Paisley, UK). EGF and bFGF for routine cell maintenance were
from Peprotech (London, UK). Laminin and optical grade dimethyl
sulfoxide (DMSO) were from Sigma-Aldrich (Poole, UK). Poly-D-lysine
was from Millipore (Consett, UK).
2.2. Synthesis of dextrin-growth factor conjugates
Succinoylated dextrin (27.8 mol% succinoylation, 74,000 g/mol)
was synthesized according to the method of Hreczuk-Hirst et al.
(Hreczuk-Hirst et al., 2001) and characterized as described by Ferguson
and Duncan (2009). The succinoylated dextrin intermediate was con-
jugated to EGF using EDC and sulfo-NHS as coupling agents, as de-
scribed by Hardwicke et al. (Hardwicke et al., 2010b). For dextrin-bFGF
conjugation, a modiﬁed version of the same method was employed,
however, since bFGF's molecular weight is 2.8 times greater than EGF, a
molar ratio of 1 bFGF to 1 dextrin was used. Brieﬂy, succinoylated
dextrin (11.8mg, 2.3× 10−7 mol) was dissolved under stirring in
ddH2O (800 μL) in a 10mL round-bottomed ﬂask. To this, EDC (2mg,
1.0×10−5 mol) and sulfo-NHS (2mg, 9.2× 10−6 mol) were added
and the solution was stirred for 15min. Next, bFGF (4mg,
2.3×10−7 mol) was added and the pH adjusted to 8.0 by dropwise
addition of NaOH (0.5M) before allowing the reaction to proceed for
2 h. The products were puriﬁed using FPLC, prior to lyophilization and
storage at −20 °C.
Conjugates were characterized in respect of free protein by FPLC
(ÄKTA Puriﬁer; GE Healthcare, UK) using a pre-packed Superdex 75
10/300 GL column with a UV detector and data analysis using Unicorn
5.20 software (GE Healthcare, UK). Samples (200 μL) were injected into
a 100 μL loop with a 0.1M phosphate buﬀer with 0.15M sodium
chloride (PBS), pH 7.4 at 0.5 mL/min. The molecular weight was esti-
mated relative to protein standards. The total protein content of the
conjugate was determined by the BCA assay.
2.3. Degradation of dextrin-EGF conjugates by amylase
To compare the concentration-dependent rate of amylase degrada-
tion of dextrin-EGF conjugates, solutions (1mg/mL in PBS, pH 7.4)
were prepared containing amylase (0, 20, 93 IU/L in PBS) and in-
cubated at 37 °C for up to 168 h. At various time-points, samples
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(150 μL) were taken, immediately snap frozen in liquid nitrogen to stop
the reaction and then stored at−20 °C until analysis. The samples were
thawed and analyzed by FPLC to determine the change in % free EGF
over time by comparing the ratio of the area under the curve corre-
sponding to free and dextrin-conjugated EGF.
2.4. Cell culture
All cells were routinely grown in a 75 cm3 tissue culture ﬂasks and
incubated at 37 °C/5% CO2. HEp2 cells were cultured in EMEM media
containing heat-inactivated FCS (10% v/v) and antibiotic-antimycotic
solution. HEp2 cell monolayers were detached from the surface using
trypsin-EDTA solution. mNSCs were cultured in DMEM/F12 media
containing N2 (1% v/v), EGF (10 ng/mL) and bFGF (10 ng/mL).
Neurospheres were digested to single cells using StemPro® Accutase®.
2.5. Evaluation of cell proliferation by MTT assay: Restoration of biological
activity by amylase
An MTT assay (Mosmann, 1983) was used to assess cell proliferation
(72 h incubation) in HEp2 cells in the presence of dextrin-EGF con-
jugate that had been pre-exposed to varying physiological concentra-
tions of amylase. Here, dextrin-EGF conjugate (50 ng/mL EGF equiv.)
was incubated with amylase (0, 20, 93 IU/L) in serum-free media for
24 h at 37 °C, prior to adding to the cells. Meanwhile, cells were seeded
into the inner wells of sterile 96-well microtiter plates (2.5× 104 cells/
mL) in 0.1mL/well of serum-free media to excluded interference from
other sources of EGF. Outer wells were ﬁlled with sterile PBS (0.1 mL/
well) and cells were allowed to adhere for 24 h. The medium was then
removed and test compounds (0.2 μm ﬁlter-sterilized) were added.
After 67 h, MTT (20 μL of a 5mg/mL solution in PBS) was added to each
well and the cells were incubated for a further 5 h. The medium was
then removed and the precipitated formazan crystals solubilized by
addition of DMSO (100 μL). Absorbance was measured at 550 nm after
30min using a microtiter plate reader. Cell viability was expressed as a
percentage of the viability of untreated control cells.
2.6. Monolayer response model
Cell proliferation was assessed daily over 7 days using an MTT assay
as previously described (Mosmann, 1983). Brieﬂy, cells were seeded
into the inner wells of sterile poly-D-lysine/laminin coated 96-well
microtiter plates (5× 104 cells/mL) in 0.1mL/well of media containing
N2 (1% v/v), EGF (10 ng/mL) and bFGF (10 ng/mL) at 37 °C/5% CO2.
Outer wells were ﬁlled with sterile PBS (0.1 mL/well). Cells were al-
lowed to adhere for 24 h. The medium was then removed and ﬁlter-
sterilized (0.2 μm) test compounds dissolved in DMEM/F12 media
containing N2 supplement were added to the cells as follows: (1) con-
trol (no growth factors); (2) EGF (10 ng/mL) and bFGF (10 ng/mL); (3)
dextrin-EGF (10 ng/mL EGF equiv.) and bFGF (10 ng/mL); (4) EGF
(10 ng/mL) and dextrin-bFGF (10 ng/mL bFGF equiv.); and (5) dextrin-
EGF (10 ng/mL EGF equiv.) and dextrin-bFGF (10 ng/mL bFGF equiv.).
Proliferation was monitored daily using an MTT assay, as described
previously, and cell viability was expressed as a percentage of the ab-
sorbance reading on day 0. Data were normalized to the presence or
absence of EGF+bFGF (EGF+bFGF and EGF/bFGF-free medium
were set at 100% and 0%, respectively). Pictures of the wells of a 24-
well plate treated as described above were taken immediately after
addition of treatments (t=0) and daily thereafter using a Canon
PC1234 digital camera, (Japan) attached to a Nikon Eclipse TS100 light
microscope (UK).
2.7. Three-dimensional sphere response model
To study cell proliferation eﬀects in a 3-dimensional model, cells
were seeded into the inner wells non-coated 96-well microtiter plates
(5×104 cells/mL) in 0.1mL/well of media containing N2 (1% v/v),
EGF (10 ng/mL) and bFGF (10 ng/mL) at 37 °C/5% CO2. Outer wells
were ﬁlled with sterile PBS (0.1 mL/well). Treatments were added after
24 h as previously described and proliferation was monitored daily
using an MTT assay and visually by a microscope. Data were normal-
ized to the presence or absence of EGF+bFGF (EGF+ bFGF and EGF/
bFGF-free medium were set at 100% and 0%, respectively). In vitro cell
proliferation was also studied by analysis of neurosphere number and
mean diameter. Pictures of the wells of a 96-well plate treated as de-
scribed above were taken immediately after addition of treatments
(t= 0) and daily thereafter using a Canon PC1234 digital camera,
(Japan) attached to a Nikon Eclipse TS100 light microscope (UK). The
number of neurospheres and their average diameter was screened using
random sampling (1 visual ﬁeld per well, n= 6) and quantiﬁed using
ImageJ software (Rasband, 1997–2015). Neurospheres were classed
based on their mean diameter: small (50–100 μm), medium
(100–200 μm) and large (≥200 μm). Neurospheres on the edges of each
image were excluded from analysis, so that only completely visualized
spheres were quantiﬁed.
2.8. Evaluation of apoptosis in mNSC
To assess apotosis of the mNSC, cells were seeded into the inner
wells of 24-well microtiter plates (5×104 cells/mL) in 0.6 mL/well of
media containing N2 (1% v/v), EGF (10 ng/mL) and bFGF (10 ng/mL)
at 37 °C/5% CO2. Outer wells were ﬁlled with sterile PBS (2mL/well).
Treatments (1 mL) were added after 24 h as previously described and
apoptosis was analyzed using a DeadEnd™ Fluorometric TUNEL system
(Promega, UK) following the manufacturer's instructions. Cells were
counterstained with DAPI contained in Vectashield mounting medium
(Vector Laboratories, Peterborough, UK) and imaged using an ultra
violet (UV) microscope (Olympus AX70 with a Digital Eclipse DX
M1200 digital camera attachment (Japan). The images were captured
using the Automatic Camera Tamer (ACT-1) control software (Nikon
Digital, Japan) at λex= 373 nm, λem=456 nm (DAPI) and
λex= 490 nm, λem=520 nm (FITC). The number of TUNEL-positive
cells (deﬁned as a TUNEL signal that overlapped with the DAPI stained
nuclei) was screened using random sampling (2 visual ﬁelds per well,
n= 2) and expressed as the percentage of TUNEL-positive cells out of
the total number of mNSCs counted.
2.9. Immunoﬂuorescent analysis of mNSC properties
Following the same plate set-up procedure as the apoptosis assay,
cells were prepared for immunoﬂuorescent analysis immediately after
addition of treatments (t=0) and on days 5 and 7. Brieﬂy, mNSCs were
ﬁxed with freshly prepared paraformaldehyde solution (4% v/w in PBS)
for 20min, permeabilized with 0.2% Triton X-100 for 10min and in-
cubated in blocking solution (1% BSA in PBS) for 1 h at room tem-
perature, followed by incubation with primary antibodies at 4 °C
overnight. After extensive washing with the blocking solution, cells
were incubated with secondary antibodies at 37 °C for 1 h. Then,
mNSCs were mounted in Vectashield mounting medium with DAPI. All
antibodies were diluted in blocking solution. The primary antibodies
used were nestin, a monoclonal marker for neural stem cells (1:100,
Santa Cruz SC-33677); MAP2, a polyclonal antibody speciﬁc for neu-
rons (1:250, Millipore AB5622); GFAP, a monoclonal antibody speciﬁc
for astrocytes (1:500, Millipore 04–1062) and Olig2, a polyclonal an-
tibody speciﬁc for oligodendrocytes (1:500, Millipore AB9610). The
secondary antibodies were Alexa 594-conjugated goat anti-mouse and
anti-rabbit IgGs, (1:500; Life Technologies, UK).
Confocal ﬂuorescence microscopy was performed using an inverted
Leica SP5 Confocal laser scanning microscopy (CLSM) and a x63 oil
immersion lens, with a scan speed of 400 Hz. Data was collected using
Leica LAS AF software and exported as tagged image ﬁles (TIF); at least
3 representative images were obtained for each sample. Typical results
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are shown. Merged images were generated using the Leica LAS AF
software. To determine the percentage of the nestin/GFAP/MAP2/
Olig2-positive cells, the numbers of DAPI-labeled cell nuclei and those
double-labeled with AlexaFluor 594 were counted. Nestin/GFAP/
MAP2/Olig2 expression was qualiﬁed and quantiﬁed using random
sampling.
2.10. Statistical analysis
Data are expressed as mean ± the error, calculated as either stan-
dard deviation (SD) where n= 3, or standard error of the mean (SEM)
where n > 3. Statistical signiﬁcance was set at p < .05 (indicated by
*). Evaluation of signiﬁcance was achieved using a one- or two-way
analysis of variance (ANOVA) followed by Bonferroni post hoc tests that
correct for multiple comparisons. All statistical calculations were per-
formed using GraphPad Prism, version 6.0 h for Macintosh, 2015.
3. Results
Dextrin-EGF and -bFGF conjugates used in these studies had an
average protein content of 3.9 (equivalent to 3 dextrin: 1 EGF) and
6.7% w/w protein (equivalent to 4.7 dextrin: 1 bFGF), respectively. The
average molecular weight was 190,000 and 180,000 g/mol, for dextrin-
EGF and –bFGF, respectively. FPLC indicated that the free protein
content of the conjugates was always< 1%. Neither dextrin-EGF or
dextrin-bFGF conjugates were cytotoxic towards mNSC, up to 500 ng/
mL growth factor equiv. (measured by MTT assay, 72 h incubation; data
not shown).
3.1. Eﬀect of amylase concentration on dextrin-EGF conjugate stability and
activity
FPLC analysis of amylase-treated dextrin–EGF conjugate showed a
time- and concentration-dependent increase in concentration of free
EGF, indicating release of EGF from the conjugate due to amylase de-
gradation of dextrin. In these experiments, 93 IU/L amylase released
the most free EGF (~91.1%) after 168 h incubation (Fig. 1A), however,
signiﬁcant EGF release was observed at amylase concentrations similar
to those found in cerebrospinal ﬂuid (20 IU/L) (77.1% after 168 h in-
cubation).
In the HEp2 cell proliferation model, dextrin-EGF conjugate activity
(in the absence of amylase) was not signiﬁcantly diﬀerent to control
(p > .05) but was signiﬁcantly lower than free EGF (p < .01)
(Fig. 1B). When conjugates were pre-incubated with amylase, HEp2 cell
proliferation was restored in a concentration-dependent manner,
whereby amylase concentrations of 93 IU/L produced no signiﬁcant
diﬀerence in cell proliferation after 72 h compared to free EGF
(p > .01).
3.2. Stimulation of mNSC proliferation
To quantify the mitogenic activity of dextrin-growth factor con-
jugates, the proliferation proﬁle of mNSCs during incubation with free
and/or dextrin-conjugated growth factors was examined for 7 days
(Fig. 2). When adherent cells were grown in the absence of growth
factors, no proliferation was observed (Fig. 2A). In contrast, prolifera-
tion of mNSC exposed to unbound growth factors stimulated cell pro-
liferation which peaked at day 5, with a corresponding decrease in cell
density and morphological changes thereafter. Supplementation with
one ‘free’ (unconjugated) and one conjugated growth factor showed a
similar proliferation proﬁle, but with more viable cells from day 5 than
was observed with free growth factors. The addition of dextrin-EGF and
-bFGF conjugates led to the greatest number of viable cells and pro-
longed proliferation, which only showed a drop in cell viability after
day 6, when conﬂuency had been reached (p < .0001 compared to
EGF+bFGF).
Similarly, when cells were grown in uncoated plates, to allow
neurosphere formation, supplementation with dextrin-EGF and -bFGF
conjugates led to the greatest and most prolonged proliferation of
mNSCs, that did not reach a peak within 7 days (Fig. 2B). Treatment
with unconjugated growth factors led to maximal cell viability on day
4, which was lower than the other treatments, and followed by a gra-
dual decrease in viable cell numbers thereafter. Neurospheres grown in
the presence of dextrin-EGF+ bFGF showed comparable proliferation
to the combined dextrin-growth factors, while the EGF+dextrin-bFGF
combination was only modestly better than free growth factors. When
neurospheres were categorized according to size, those grown in the
presence of dextrin-conjugated growth factors were more abundant
than those cultured with unbound growth factors (Fig. 2C,D). Neuro-
spheres grown in the presence of the dextrin-conjugated growth factors
also appeared more dense (data not shown).
3.3. Detection of apoptosis in growth factor-treated mNSC
TUNEL labeling was used to study apoptosis of mNSC grown in
coated plates at the cellular level. In the absence of growth factors,
numbers of TUNEL-positive cells increased signiﬁcantly from day 0 to 7
(47.4% ± 12.6 (SD) TUNEL-positive cells, p < .0001); cells exhibited
the characteristic fragmented nuclei (Fig. 3). Supplementation with free
or dextrin-conjugated growth factor treatments did not trigger sig-
niﬁcant cell apoptosis after 7 days (< 5% TUNEL-positive cells).
3.4. Evaluation of mNSC characteristics by immunoﬂuorescence
To investigate the stem cell characteristics of mNSCs, nestin ex-
pression was visualized in adherent cells by immunocytochemistry
Fig. 1. Stability of dextrin-EGF conjugate in physiologically relevant con-
centrations of amylase. (A) Release of EGF from dextrin-EGF conjugates (1 mg/
mL) in the absence and presence of amylase (20–93 IU/L in PBS) at 37 °C
(measured by FPLC). Data is expressed as the percentage of total EGF (n=1).
(B) Proliferation of HEp2 cells (72 h incubation) in the presence of EGF or the
dextrin-EGF conjugate (6.25 ng/mL EGF equiv.) with amylase (0–93 IU/L).
Data represents mean ± SD, n=6. * indicates signiﬁcance p < .01 compared
to control (no GF).
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(Fig. 4A). Cells grown in the absence of any growth factors (control)
showed reduced nestin-positivity after 7 days (37.1% ± 14.5 (SD)
nestin-positive cells, p < .0001) (Fig. 4B). No statistically signiﬁcant
alteration in the proportion of nestin-positive cells was observed in any
of the growth factor-treated groups, however, there was a trend for
slightly reduced nestin expression in cells treated with unconjugated
bFGF (EGF+ bFGF (80.2% ± 5.4 (SD) nestin-positive cells) and dex-
trin-EGF+bFGF (81.1% ± 20.1 (SD) nestin-positive cells) compared
to dextrin-conjugated bFGF (EGF+dextrin-bFGF (98.8% ± 2.1 (SD)
nestin-positive cells) and dextrin-EGF+ dextrin-bFGF (96.7% ± 8.2
(SD) nestin-positive cells) after 7 days.
To determine whether mNSCs maintained their ability to diﬀer-
entiate in the presence of dextrin-conjugated growth factors, the ex-
pression of neuron, astrocyte and oligodendrocyte lineage markers was
assessed by confocal ﬂuorescent microscopy of immune-labeled cells
(Fig. 4). Control cells, grown in the absence of any growth factors,
showed elevated expression of MAP2 (p < .001) and GFAP (p < .01),
and reduced expression of Olig2 (p < .001), compared to the cells on
day 0 (Fig. 4C,D,E). Cells treated with unconjugated bFGF showed in-
creased diﬀerentiation to a neuronal lineage (EGF+bFGF
(74.4% ± 10.0 (SD), p < .0001) and dextrin-EGF+bFGF
(60.6% ± 14.7 (SD), p < .001) vs. control (30.0% ± 10.0 (SD))
MAP2-positive cells), whereas supplementation with the dextrin-
growth factor combination conjugates did not alter marker expression
after 7 days incubation. Combining free EGF with dextrin-bFGF con-
jugates had no eﬀect on expression of any of the diﬀerentiation mar-
kers.
4. Discussion
Stem cell therapy could potentially oﬀer life-altering improvements
in function, mobility and pain for patients with SCI, due to their ability
to diﬀerentiate into the many diﬀerent cell types that make up the
spinal cord. Ideally, a stem cell therapy for treating neuronal injuries
should be generated using eﬃcient, cost-eﬀective strategies to produce
high numbers of homogeneous undiﬀerentiated stem cells. Clinically,
the stem cell therapy must be capable of replacing injured cells, to
produce aligned ﬁbers of diﬀerentiated cells, with minimal scar tissue
formation. Stem cells would be administered in a single (or infrequent)
operative procedure in a medium that can support proliferation and
diﬀerentiation for an extended period by sustained delivery of nutrients
and growth factors (Coelho et al., 2012). Here, we have shown that the
use of biodegradable dextrin-bFGF and -EGF conjugates can increase
and prolong the proliferation of mNSC while simultaneously inhibiting
apoptosis. Furthermore, mNSCs retain their stem cell properties and
demonstrate the ability to diﬀerentiate into nerve cells. These ob-
servations demonstrate, not only, that dextrin-growth factor conjugates
may be used to support in vitro stem cell proliferation and diﬀerentia-
tion via sustained, controllable growth factor release, but may, in the
future, be used to improve the delivery, and ultimate fate, of stem cells
in transplantation-based repair of SCI and other neuronal injuries.
Duncan et al. have previously shown that controlled reinstatement
of protein activity is achieved by degradation of dextrin by physiolo-
gical (serum) concentrations of amylase (Duncan et al., 2008). How-
ever, since cerebrospinal ﬂuid reportedly contains ~12–17 IU/L amy-
lase (Lahiri, 1973) (compared to 30–110 IU/L in serum), our ﬁrst
experiments investigated whether controlled release and reinstatement
Fig. 2. Proliferation of mNSC over 7 days. Growth curves (using the MTT assay) of cells grown as (A) a monolayer and (B) neurospheres, when cells were grown in
growth factor-free medium (control), or in the presence of free- or dextrin-conjugated EGF and bFGF. Data represent mean ± SEM, n= 18. Categorization of
neurospheres based upon diameter: small (100 μm), medium (100–200 μm) and large (> 200 μm) on (C) day 5 and (D) day 7. Data represent mean ± SEM, n= 6.
Where error bars are invisible they are within size of data points. *Indicates signiﬁcance p < .0001 compared to EGF+bFGF. Values above bars correspond to mean
total neurosphere number ± SEM, n= 6.
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of growth factor activity could be achieved at these lower amylase
concentrations, using dextrin-EGF as a model (Fig. 1). Here, a con-
centration-dependent increase in rate and extent of EGF release in the
presence of low concentrations of amylase was observed; mirrored by
the restoration of HEp2 cell proliferation following pre-incubation with
equivalent concentrations of amylase. This slower release of growth
factor from the conjugate at lower amylase concentrations may be
clinically useful, as stem cells administered to treat SCI would take
several weeks to generate a functional nerve ﬁber. Similarly, exposure
of mNSC to growth factors stimulated cell proliferation, which was
greater and more prolonged when growth factors were conjugated to
dextrin; demonstrating the increased stability and sustained release of
growth factors that polymer conjugation confers. Cell culture media in
these experiments was not supplemented with amylase, since this is not
routinely added to stem cell culture media, which allowed us to de-
monstrate the eﬀectiveness of dextrin-conjugated growth factors as
stem cell media supplements for the expansion of stem cells. Pre-
liminary studies were undertaken with the addition of exogenous
amylase, in an attempt to reproduce levels observed in acute and
chronic inﬂammation observed in neuronal injury and degenerative
disease. Importantly, it was evident that the release and activity of the
dextrin-conjugated growth factors occurs in the absence of amylase
(supplementary ﬁgs. S1,S2) and that the eﬀects of the conjugates were
not signiﬁcantly reduced. This ﬁnding may reﬂect enzymatic activity of
the cells e.g. lysosomal glycosidase production. The addition of exo-
genous amylase led to increased stem cell numbers compared to the
amylase-free treatment that decreased or plateaued in 2D and 3D
cultured cells, respectively, after day 5. Based on these results, it is
envisaged that the use of dextrin-conjugated growth factors could sig-
niﬁcantly improve the eﬃciency of not only stem cell maintenance and
expansion (reducing the necessity for growth factor supplementation by
up to 7-fold), but also could be employed clinically at inﬂamed sites.
It is well known that EGF and bFGF are essential for the prolifera-
tion and expansion of neural stem cells (Gritti et al., 1996; Kornblum
et al., 1990; Morrison et al., 1988; Morrison et al., 1987; Kojima and
Tator, 2002). Recent studies have shown that sustained growth factor
levels decrease spontaneous diﬀerentiation and increase proliferation,
yet this is not achieved in routine stem cell maintenance, even with
daily culture medium replacement (Lotz et al., 2013). For example, Lotz
et al. (Lotz et al., 2013) showed that FGF-2 levels fell to below 50% of
the initial concentration within 4 h, and<25% remained after 24 h,
presumably due to denaturation of FGF-2 by heat (Chen et al., 2012),
proteolytic enzymes and growth factor-solvent interactions. Conse-
quently, encapsulation into a polyelectrolyte-modiﬁed 2-hydroxyethyl
methacrylate hydrogel (Galderisi et al., 2013), poly(lactic-co-glycolic
acid) (PLGA) microspheres (Lotz et al., 2013) and multi-trilayered na-
noﬁlms (Han et al., 2017) have been investigated to achieve controlled
release of FGF-2 in stem cell culture media. Controlled release of
growth factors, as a means of enhancing the proliferation of cells in the
central nervous system, has also principally involved incorporation into
polymeric hydrogels (Gupta et al., 2006; Kapur and Shoichet, 2004;
Kang et al., 2009; Jimenez Hamann et al., 2005). Generally, these
systems are designed to release all entrapped growth factors at the same
rate (either in an initial burst or within a few days), however, the
Fig. 3. TUNEL assay to detect intranuclear DNA fragmentation in apoptotic mNSC. (A) Visualization on day 7 and (B) quantiﬁcation on days 0, 5 and 7 of TUNEL-
positive cells (indicated with white arrows). In all microscopy images, the left-hand column represents data shown in the green (FITC) channel, the middle column
represents data shown in the blue (DAPI) channel and the data shown in the right-hand column represents merged data. Scale bar= 100 μm. Data represent
mean ± SEM, n= 8. * indicates signiﬁcance p < .0001 compared to day 0. (For interpretation of the references to colour in this ﬁgure legend, the reader is referred
to the web version of this article.)
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physiological growth factor signalling cascade is much more complex.
Consequently, Bauman et al. developed a composite drug delivery
system for independent delivery of multiple drugs entrapped within an
injectable hyaluronan (2% w/w) and methyl cellulose (7% w/w)
(HAMC) hydrogel containing PLGA nano- and microparticles (Baumann
et al., 2009). In a model system designed to treat SCI, rapid, diﬀusion-
controlled release of neuroprotective molecules (e.g. bFGF) from the
HAMC hydrogel was achieved over 1–4 days, while slow release of
neuroregenerative molecules (e.g. EGF) over 28 days was attained by
entrapment within the PLGA particles. This concept of sustained com-
bination therapy mimics the physiological release of growth factors and
could usefully applied to the dextrin- growth factor conjugates devel-
oped in these studies. Modiﬁcation of dextrin's molecular weight and
degree of succinoylation have been demonstrated to control the
polymer's degradation rate (Duncan et al., 2008), thereby altering the
release rate of growth factors. Conjugation of colistin to 1mol% suc-
cinoylated 7500 g/mol dextrin led to ∼80% drug release by amylase
degradation within 48 h (Ferguson et al., 2014), compared to 52.7%
after 168 h for EGF conjugated to 19mol% succinoylated 42,000 g/mol
dextrin (Hardwicke et al., 2010b). Since the desired exposure to bFGF is
days (vs. weeks for EGF), this could readily be achieved by its con-
jugation to a lower molecular weight dextrin with less modiﬁcation.
Growth factor withdrawal is widely recognised as a trigger for
programmed cell death, due to mitochondrial cytochrome C release and
caspase activation (Letai, 2006). It therefore follows, that if exogenous
growth factors are depleted or degraded in the cell environment, re-
duced stem cell viability would be accompanied by apoptosis. We,
therefore, used a TUNEL assay to detect apoptotic cells during
Fig. 4. (A) Detection of NSC and diﬀerentiation markers. Experiments conducted in mNSC grown in growth factor-free medium (control), or in the presence of free-
or dextrin-conjugated EGF and bFGF by visualization of nestin/GFAP/MAP2/Olig2-positive cells on days 0, 5 and 7. In all microscopy images, all ﬁgures represent
merged data from the red (Alexa Fluor® 594) and blue (DAPI) channels. Scale bar= 100 μm. Quantiﬁcation of (B) nestin, (C) MAP2, (D) GFAP and (E) Olig2-positive
cells on day 7. Data represent mean ± SD, n=3. *Indicates signiﬁcance p < .01 and **indicates signiﬁcance p < .001, compared to day 0. (For interpretation of
the references to colour in this ﬁgure legend, the reader is referred to the web version of this article.)
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incubation with free and dextrin-conjugated growth factor for 7 days.
As expected, mNSCs grown in the absence of any growth factors (con-
trol) showed signiﬁcant apoptosis after 7 days, however, while cell
viability of free growth factor-treated mNSCs was clearly reduced after
7 days compared to dextrin-conjugated growth factors, apoptosis was
not induced in any of the treatment groups. While these results suggest
that free growth factors were not depleted or degraded over the 7-day
incubation period, it is important to note that the TUNEL assay detects
extensive DNA fragmentation which occurs only in the late stages of
apoptosis (Kyrylkova et al., 2012). It is, therefore, possible that cells
treated with unconjugated growth factors were in the early stages of
apoptosis due to growth factor depletion, that would be undetectable in
this assay. Moreover, in addition to apoptosis, growth factor depriva-
tion may promote a death autophagy-like mechanism characterized by
vacuole development, which is also undetectable by conventional
TUNEL assay (Cardenas-Aguayo Mdel et al., 2003).
Indiscriminate diﬀerentiation of neural stem cells occurs in response
to growth factor withdrawal (Johe et al., 1996), therefore, it was hy-
pothesized that sustained release of growth factors from polymer con-
jugates could suppress diﬀerentiation and maintain a homogeneous
population of multipotent stem cells. As expected, in these experiments,
mNSCs showed dramatically reduced expression of the neural pro-
genitor-associated marker nestin following growth factor withdrawal,
associated with initiation of diﬀerentiation. In contrast, expression of
nestin was unaltered in all the growth factor-treated mNSC treatment
groups, suggesting that the cells had retained their neural stem cell
identity over the 7-day incubation period. However, im-
munocytochemical evaluation demonstrated that, while addition of
dextrin-conjugated EGF and bFGF did not change the expression of
neuron, astrocyte and oligodendrocyte diﬀerentiation markers after
7 days, mNSCs treated with free growth factors showed some altered
expression of diﬀerentiation markers, suggesting that growth factor
depletion had occurred, presumably due to proteolytic degradation.
GFAP expression was also signiﬁcantly elevated in the growth factor-
free mNSCs but remained unaltered in all other treatment groups. Al-
though GFAP-expressing astrocytes may enhance repair following SCI,
they also have a signiﬁcant role in the formation of glial scar tissue
(Sofroniew and Vinters, 2010), which inhibits functional recovery and
creates a barrier to regeneration (Silver and Miller, 2004). Clinically,
these alterations may impede regeneration of a functional spinal cord.
Interestingly, the presence of dextrin-conjugated bFGF maintained
mNSC MAP2 expression, while unconjugated bFGF led to increased
MAP2 expression, indicating that this growth factor may beneﬁt from
sustained, controlled release by dextrin conjugation. Olig2 plays an
important role in oligodendrocyte formation, however, this factor has
also been identiﬁed as a multifunctional regulator of NSC self-renewal
during expansion (Mateo et al., 2015; Hack et al., 2004) that is ex-
pressed in almost all cells cultured as neurospheres in the presence of
bFGF and EGF (Dromard et al., 2007). It is therefore unsurprising that
withdrawal of growth factors led to decreased Olig2 expression, and
remained high in all growth factor-treated groups.
These results show the potential of dextrin-growth factor conjugates
for further development as culture media supplements for in vitro stem
cell expansion. Additionally, the results highlight the potential of bio-
polymer conjugation as an eﬃcient and eﬀective tool for localized,
sustained delivery of growth factors to increase the survival, integration
and diﬀerentiation of transplanted stem cells in vivo. Ongoing studies
are evaluating dextrin-growth factor conjugates in ex vivo and in vivo
models of SCI and investigating dextrin conjugation of other neural
stem cell-speciﬁc growth factors.
Fig. 4. (continued)
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